Add BrightSurf on Google Email

European Alliance of Associations for Rheumatology (EULAR)


US study shows that tofacitinib is an efficacious treatment for active RA

A Phase III study presented at EULAR 2011 found that tofacitinib achieved significant improvements in symptoms and activity scores for patients with active rheumatoid arthritis (RA), including improved ACR20 responses in 58.3% of patients, and a higher proportion of patients achieving ACR50 and ACR70 responses compared to placebo

SourceEuropean Alliance of Associations for Rheumatology (EULAR)·JournalAnnals of the Rheumatic Diseases·DateMay 25, 2011

RA individuals from lower GDP countries keep working despite worse symptoms than richer countries

A new multinational study found that RA individuals in lower GDP countries are more likely to keep working despite higher disease activity and functional disability scores. The probability of individuals continuing work for 2 years was 80%, while the probability of continuing to work for 5 years was 68%. This highlights the significant...

Winter- and spring-onset RA patients have worse 6 month outcomes than those with summer onset

A new study found that patients with rheumatoid arthritis (RA) whose symptoms first appear in winter or spring tend to have worse radiographic outcomes at six months compared to those with summer onset. The study suggests environmental factors such as vitamin D deficiency and winter viruses may contribute to this effect.